Dr. rer. nat. Heike Horn | Institut für klinische Pharmakologie IKP

Major Projects

MALDI-TOF MS based screening of single nucleotide polymorphisms (SNPs) in patients with follicular lymphoma
Establishment of an ex vivo culture system for follicular lymphoma
Gene expression based survival model for patients with follicular lymphoma
The role of immunophenotypic variations and genetic/epigenetic alterations in FL and DLBCL patients of the German Low Grade and High Grade Lymphoma Study Groups

Selected References

Horn H, Jurinovic V, Leich E, Kalmbach S, Bausinger J, Staiger AM, Kurz KS, Möller P, Bernd HW, Feller AC, Koch K, Klapper W, Stein H, Hansmann ML, Hartmann S, Scheubeck G, Dreyling M, Hiddemann W, Herfarth K, Engelhard M, Rosenwald A, Hoster E and Ott G for the German Low-Grade Lymphoma Study Group (GLSG). Molecular cytogenetic profiling reveals similarities and differences between localized nodal and systemic follicular lymphomas. Hemasphere 2022; 6:e767

Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, Zapukhlyak M, Berning P, Brändle M, Jarboui MA, Schönfeld C, Boldt K, Rosenwald A, Ott G, Grau M, Klener P, Vockova P, Lengerke C, Lenz G, Schulze-Osthoff K, Hailfinger S. Dimethyl fumarate induces ferroptosis and impairs NF-kB/STAT3 signaling in DLBCL. Blood 2021; 138:871-884

Horn H, Kalmbach S, Wagener R, Staiger AM, Hüttl K, Mottok A, Bens S, Traverse-Glehen A, Fontaine J, Siebert R, Rosenwald A, Ott G. A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas. Am J Surg Pathol. 2021; 45:356-364

Staiger AM, Hoster E, Jurinovic V, Winter S, Leich E, Kalla C, Möller P, Bernd HW, Feller AC, Koch K, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M, Weigert O, Hiddemann W, Herfarth K, Rosenwald A, Engelhard M, Ott G, Horn H. Localized and advanced stage follicular lymphomas differ in their gene expression profiles. Blood. 2020; 135:181-190

Zamò A, Pischimarov J, Horn H, Ott G, Rosenwald A, Leich E. The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion. Br J Haematol 2018; 180:391-394

Major Networks and Collaborations

Molecular Mechanisms in Malignant Lymphomas (MMML)
German Low Grade Lmyphoma Study Group (GLSG)

Extramural Funding

2004-2006: Graduiertenkolleg 639: ‘Molekulare und Strukturelle Grundlagen der Tumorinstabilität, Julius-Maximilians-University, Würzburg, Germany
2007-2008: Verbundprojekt der Deutschen Krebshilfe/Mildred-Scheel-Stiftung –Molekulare Mechanismen bei malignen Lymphomen Nr. 70-3173-Tr 3 Zentralprojekt A1/Teilprojekt B3/M4 2004-2009
2004-2006: European Proposal No 503351 „European Mantle Cell Lymphoma Network: Translational Determination of Molecular Prognostic Factors“

Curriculum Vitae

Education and Professional Career

01/2008-present

Principal Investigator, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Research Group of the Institute of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany (Head Prof. G. Ott)

2007-2008

Postdoctoral research fellow: Investigation of HIC1 tumor suppressor gene in mantle cell lymphoma. / Molecular characterization of follicular lymphomas. Institute of Pathology, Julius-Maximilians-University, Würzburg, Germany (Head Prof. H.-K. Müller-Hermelink)

2007

Dr. rer. nat. (PhD) in biology, Julius-Maximilians-University, Würzburg, Germany

2004-2007

PhD Thesis: ‘Characterization of 17p-deletions in diffuse large B-cell lymphoma and identification of HIC1 as a novel tumor suppressor gene’, Institute of Pathology, Julius-Maximilians-University, Würzburg, Germany

2004

Diploma degree for biology

1999-2004

Study of biology, Julius-Maximilians-University, Würzburg, Germany

Research Group

PharmacoOmics & Lymphoma